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lines. METHODS: Data from the National Ambulatory
Medical Care Survey (NAMCS) 1997 was utilized. Pa-
tients with principal diagnosis of otitis media with age
less than or equal to 12 years were analyzed using multi-
ple linear and binomial logit regression models. Appro-
priate antibiotics are defined as those that are recom-
mended by the guidelines. The average wholesale price of
recommended antibiotics was compared with the inap-
propriate antibiotics prescribed. The dosage of antibiot-
ics was confirmed by the IMS health and the advice of a
practicing Otolaryngologist. Antibiotics cost was calcu-
lated by using the Red Book 1997 and 1998. The
weighted average method was used to calculate the aver-
age wholesale price of the various quantity packages and
dosage forms. This study utilized the methodology of re-
lating a secondary database to an outside source (Red
Book) to calculate the cost. RESULTS: The average cost
of a course of appropriate antibiotic (penicillin and its de-
rivatives) was found to be $8.07, compared to $69.56 for
expensive antibiotics (difference  $61.49). Children less
than four years of age were prescribed more expensive
antibiotics (R2  0.287). Pediatricians, and Otolaryngol-
ogists prescribed appropriate and less expensive antibiot-
ics than other family physicians (R2  0.144). There was
no relationship between the physician’s specialty and pa-
tient’s age for inappropriate antibiotics prescribing (R2 
0.345). CONCLUSIONS: Adhering to the guidelines and
prescribing of appropriate antibiotics appears to save
cost. Inappropriate prescribing of antibiotics for otitis
media should be addressed more explicitly in general
practice.
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COST-EFFECTIVENESS OF ARTIFICIAL SKIN 
SUBSTITUTE VS ALLOGRAFT FOR
BURN PATIENTS
Bron MS, Hay J
University of Southern California, Los Angeles, CA, USA
INTRODUCTION: Healing after a burn injury requires
a temporary wound cover until the skin epithelium heals.
Traditional wound covering, human cadaver allograft
(HCA), is expensive, and limited by availability. OBJEC-
TIVE: To determine if artificial skin substitute (Tran-
scyte) wound cover is cost-effective for temporary wound
coverage in patients with major total body surface
(TBSA) burns. METHODS: Incremental cost per quality
adjusted life year (QALY) in 2000 US dollars is estimated
assuming a base case adult patient who has 40% TBSA
burn with no inhalation injury, complications, or facial
burn followed for one year after HCA or Transcyte pro-
cedure. A societal perspective is used. Utilities were sur-
veyed from burn-unit hospital employees. Other vari-
ables are taken from literature. RESULTS: Under the
base case, Transcyte saves $3600 over HCA, and adds
0.04 QALYs. Quality of life was significantly greater in
the Transcyte group (0.54, 95% CI  0.48–0.59) vs.
HCA group (0.65, 95% CI  0.57–0.74, p  0.04) while
in the hospital, but not significantly different while recov-
ering at home, after recovery, and at work. The incre-
mental QALY of Transcyte minus HCA must be 0.07
in order for the ICER to reach a threshold of $50,000.
Sensitivity analysis shows that a 33% increase in Tran-
scyte price will reach the threshold ICER of $50,000. In
addition, this model is highly sensitive to utility at work;
a 22% decrease of at-work utility with Transcyte will re-
sult in an ICER greater than $50,000. CONCLUSIONS:
The results show that use of Transcyte as a temporary
wound covering for 40% TBSA burns is a dominant
strategy relative to standard HCA. Use of this artificial
skin results in cost savings, due to faster healing and less
operation room time. A gain in QALYs is seen with
Transcyte, due to less scarring and pain during the heal-
ing process.
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OBJECTIVE: To compare the total, drug, and medical
care costs of common practice and best practice manage-
ment of primary open-angle glaucoma (POAG). METH-
ODS: A Delphi panel of ophthalmologists specialized in
glaucoma management was convened in order to delin-
eate practice patterns representative of community physi-
cians (common practice), and to characterize the ideal or
optimal standards of care (best practice). A decision ana-
lytic approach was used to depict and economically
quantify the clinical sequelae under each scenario for
POAG patients initiated on medical therapy. Common
and best practice decision trees were developed for proto-
typic agents of the most commonly used first-line classes
of medications. Percentage likelihood of drug usage was
determined based upon physician consensus whereas
drug and surgical efficacy rates were determined based
upon a composite of published data. Typical drug dosing
regimens and number of medical visits, as determined by
physician consensus, were used to estimate the cost of
treatment. RESULTS: The total average annual cost of
treatment per eye was estimated at $733.85 for common
practice and $732.09 for best practice. Drug costs were
estimated at $358.66 for common practice and $341.38
for best practice. Costs of medical care were estimated at
$375.19 for common practice and $390.71 for best prac-
tice. Surgical costs comprised a larger proportion of med-
ical care costs in best practice as compared to common
practice (17.84% vs. 14.29%). In comparing best prac-
tice and common practice decision analyses, non-selective
beta-blockers were used less often whereas alpha-2 ago-
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nists were used more often as first-line medical therapy.
The probability of first-line success has been estimated at
71.2% for common practice and 72.3% for best practice.
CONCLUSION: Despite higher surgical costs and im-
proved outcomes associated with best practice manage-
ment of POAG as compared with common practice, to-
tal, drug, and medical care costs of best practice were
comparable to those of common practice.
PEE8
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GLAUCOMA (POAG)
Yu E, Hay J, Varma R, Globe D
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To determine the cost-effectiveness of the
primary treatment of primary open-angle glaucoma
(POAG) with trabeculectomy versus conventional ther-
apy. METHODS: A four-year incremental cost/quality-
adjusted life year (QALY) model (year 2000 US dollars)
of POAG using a societal perspective; including direct
and indirect costs with a 3% annual discount rate for the
base case. In the Glasgow trial, patients newly diagnosed
with POAG with an intraocular pressure of 26mmHg
and/or with glaucomatous field defects were randomized
to trabeculectomy or conventional therapy (up to three
medications). In the trabeculectomy branch, patients
would either be 1) controlled without extra medication,
2) controlled with extra medication or 3) die from natu-
ral causes. Annual chance nodes for the conventional
were 1) controlled by medication, 2) surgery or 3) death
from natural causes. QALYs were calculated assuming a
decline in utility would accompany loss in visual field. A
65-year old patient with a 5% rate of decline in utility
was used as the base case. Sensitivity analyses were per-
formed on the rate of utility decline, cost of medications,
trabeculectomy cost, and discount rate. RESULTS: For
the base case, the cost of initial trabeculectomy was
$8316 versus $6339 for conventional therapy. The incre-
mental cost was $1977 and the incremental QALY was
0.08, with ICE ratio of $24,830/QALY. CONCLU-
SIONS: Initial trabeculectomy is cost-effective for POAG.
The model was most sensitive to the rate of decline in
utility (2%) and robust to changes in the costs of medi-
cations and trabeculectomy. Limitations include the lack
of long-term clinical and QALY data on glaucoma pa-
tients with different treatments. Currently the standard of
practice in the US is to start with conventional therapy
for patients with moderate or severe glaucoma. Our re-
sults indicate that trabeculectomy may be a cost-effective
option for these patients.
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EFFECTS ON HEALTH CARE CONTACTS AND 
DAYS ABSENT FROM WORK WITH 
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MAINTENANCE TREATMENT OF CROHN’S 
DISEASE IN A US SETTING
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INTRODUCTION: Crohn’s disease (CD) is a debilitat-
ing chronic disease. It also has economic implications
(both for patient and society). Reduced work (or school)
attendance and continuous need for health care contacts
are two important aspects. Data comparing the impact of
different treatment approaches are scarce. OBJECTIVE:
To assess health care utilisation and absence for work (or
school) in a US setting of patients treated with budes-
onide CIR maintenance therapy compared to patients
with no maintenance treatment (placebo). A societal per-
spective was adopted. METHODS: Data was collected in
a double-blind randomised clinical trial comparing
budesonide CIR 6 mg daily with placebo for a one year
period. Patients, 55 in each group, had CD localised to
the distal ileum and/or the ascending colon and were be-
tween the ages of 18 and 73 (mean 40.3 and 40.5 years).
The collected data included physician visits, different mi-
nor procedures (e.g., radiographic, endoscopic), medica-
tions, hospitalisations and surgical procedures. Number
of days of absence due to symptoms or treatment of the
disease was also collected. All resource utilisation related
to the design of the clinical trial was excluded in order
not to overestimate real health care use and productivity
losses. RESULTS: The budesonide CIR treatment group
had 26.3% fewer physician visits (87.14 vs. 118.27 ns)
and 27% fewer days absent from work or school (311.73
vs. 427.23 days ns). Numerical differences in other vari-
ables were smaller but in favour of budesonide CIR.
CONCLUSION: Treatment with budesonide CIR cap-
sules suggests benefits in terms of reduced health care re-
source utilisation and absence from work (school), that
also could represent favourable cost implications in the
delivery of health care.
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ALTERNATIVE MANAGEMENT STRATEGIES
FOR DYSPEPSIA
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OBJECTIVE:To compare the cost-effectiveness of alter-
native dyspepsia management strategies: (1) H. pylori
testing; if seropositive, providing H. pylori eradication
treatment using oral omeprazole, clarithromycin, and
amoxicillin; (2) empiric antisecretory therapy using ome-
prazole. METHODS: Decision analytical models com-
pared cost/QALY for alternative strategies in patients
